Continuum Advisory’s Aurora Cannabis ACB Stock Holding History

Continuum Advisory’s Portfolio ACB Stock Details ACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4	Closed	-$18	–	428
2025 Q1	$18	Sell	4 -5	-56%	-$24	﹤0.01%	1651
2024 Q4	$38	Hold	9	–	–	﹤0.01%	1836
2024 Q3	$39	Buy	9 +5	+125%	+$30	﹤0.01%	1899
2024 Q2	$18	Hold	4	–	–	﹤0.01%	1700
2024 Q1	$27	Buy	+4	New	+$15	﹤0.01%	1690

Other funds holding ACB

Tidal Investments Milwaukee, Wisconsin $47.4B AUM 59.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SNT

SIG North Trading Bala Cynwyd, Pennsylvania $4.98B AUM 36.24% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

Continuum Advisory's ACB Position: Q2 2025 in Review

Continuum Advisory sold out of Aurora Cannabis (ACB) in Q2 2025, closing a stake of 4 shares — an estimated $18 sold.

Continuum Advisory first reported a position in ACB in Q1 2024 and held it in 5 quarters. The position peaked at $39 in Q3 2024. 158 funds tracked by Wall St. Rank hold ACB as of Q2 2025.

Continuum Advisory reported no remaining Aurora Cannabis position as of Q2 2025 after selling out during the quarter.
Continuum Advisory sold 4 Aurora Cannabis shares in Q2 2025, an estimated $18.
Continuum Advisory first reported a position in Aurora Cannabis in Q1 2024 and held it in 5 quarters.
Continuum Advisory's Aurora Cannabis position peaked at $39 in Q3 2024.
158 funds tracked by Wall St. Rank held Aurora Cannabis as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.